Introduction
Menopause can be a challenging stage of life. Hot flashes are associated with a decreased quality of life (Groeneveld et al, 1996) and are a primary reason that midlife women seek medical care (Anderson et al, 1987).
According to a recent Gallup Poll, 80 percent of menopausal, post menopausal or surgically menopausal women reported having some symptoms of menopause. Among the women who had symptoms, the most common were: hot flashes (72%), irregular periods (50%), emotional responses (49%), changes in sexual relationship (31%).

There is strong evidence from randomized controlled trials that estrogen therapy is highly effective in controlling vasomotor symptoms (Manson & Martin, 2001) and urogenital symptoms (Cardozo et al, 1998). The benefits of HRT to prevent osteoporosis appear to be confined to current or recent users, and it is unlikely that taking estrogen therapy in the first decade after menopause protects against fractures later in life (median age of hip fracture is 80 years) [ Ettinger & Grady, 1993]. The use of HRT to control menopause symptoms is not without risk. There are definite increased risks of venous thrombo-embolism and endometrial cancer (Grady et al, 1995), and probable increased risks of breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormone replacement therapy, 1995) and ovarian cancer (Rodriguez et al, 2001). It is uncertain whether it has any protective effects against cardiovascular disease (Hahn et al, 1998; Herrington et al, 2000) or cognitive decline (Mulnard, 2000).
It is understandable given the above reported side effects why there has been more reluctance recently on the part of women to take HRT and more caution on the part of doctors to issue it so freely.

A previous double blind placebo-controlled study reported that the static magnetic device called LadyCare (LC), designed for application over the pelvic region, significantly reduced dysmenorrhoea in women (Eccles,2005). The current study was prompted by anecdotal reports from women wearing the LC device, that their menopause symptoms were significantly improved. It was decided to explore this further by conducting a survey to see how common this effect might be in a larger group of women who were experiencing menopause symptoms.

Methods
508 women with menopause symptoms responded to an advert placed in a national UK newspaper offering a free trial of the LC static magnetic device (see description of device below). No exclusions were made but they had to be experiencing symptoms that had been attributed to menopause. Subjects were asked to complete a questionnaire that requested them to report the duration of symptoms and to rate their symptoms (on a scale of 0-5 (where 1 represented very mild symptoms, not causing much interference, and occurred occasionally and 5, more severe symptoms that were majorly intrusive on a daily basis); prior to and after 1, 2 and 3 months of using the device.
In particular, the level of each symptom was graded according to the following scale:

0 = None at all
1 = Very mild, does not cause much interference, occurs occasionally
2 = Mild, causes some interference on a fairly regular basis
3 = Moderate, causes definite interference on a fairly regular basis
4 = Significant, causes definite interference on a regular basis
5 = Severe, and is majorly intrusive on a daily basis

The LadyCare Device
The LadyCare (LC, see photo A below of the device) magnetic device is designed for attachment to the under garment by magnetic force. LC is plastic coated and is comprised of two parts. The pear-shaped piece is worn inside of the ladies’ under garment, directly against the pelvis. The LC contains a 20-mm x 5-mm iron neodymium-boron magnet within the pear-shaped piece.

A . B.

Results
Twenty three different symptoms were rated in this way. Patients were instructed to wear the device 24 hours a day (except during bathing) for the duration of the 3 months. Results were analysed by an independent statistician.

It appears from the median score values, that the benefits from LC became apparent from the first month of use. In particular, for each symptom a highly statistically significant finding (p<10-5) was obtained after the 1st month of use, indicating that the level of suffering was reported to be highly statistically significantly lower after the use of LC.  

Summary of Findings

508 subjects rated their menopause symptoms on a 5 point scale prior to and after at 1, 2 and 3 months after wearing the LC device.
23 of the most common symptoms were rated
Average age of respondents was 49.7 ± 0.199[1] years
Median duration of menopause was 2.1 (1.3, 2.5)[2] years
21 of 23 symptoms were reduced highly statistically significantly (p< 10-4) after the 1st month of use of LC.
The graphs show that symptom relief was maintained after 3 months of use.
The other 2 symptoms were rated as zero across the group to begin with and so no change could be determined in this cohort

The image below shows the reported levels of reduction in all the 23 symptoms in the group:

• 8.1% of women surveyed had had a hysterectomy. This did not seem to affect the response to LC. There was no statistical difference in reduction of symptoms between those who still had a uterus and those that did not.

• 7.1% of women surveyed were taking HRT. This did not seem to affect the response to LC. There was no statistical difference in reduction of symptoms between those who were taking HRT and those that were not.

• 19.1% of the group lost weight. Median weight loss was 14 pounds (8, 17 pounds)[3] over the 3 months.

• 29% of women reported a return of their periods after using LC.

Comment:
This study was designed as a consumer survey. The results are consistent with a large body of anecdotal evidence received from women who reported a reduction of their menopause symptoms after using the LC device. On the basis of these encouraging results a formal placebo-controlled trial is now being planned. As part of the latter, we will assess female pituitary and ovarian hormone profiles to investigate possible mechanisms of action.

Please Click Here to download our graphs of further findings about Magnopulse LadyCare

References
Anderson E, Hamburger S, Liu JH, Rebar RW. Characteristics of menopausal women seeking assistance. Am J Obstet Gynecol. 1987;156:428 –33.

Cardozo L, Bachmann G, et al. Meta-analysis of estrogen therapy in the
management of urogenital atrophy in postmenopausal women: second report
of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998; 92:
722-727

Eccles N.K (2005). A Randomized, Double-Blinded, Placebo-Controlled Pilot Study to Investigate the Effectiveness of a Static Magnet to Relieve Dysmenorrhea. Accepted for publication. Journal of Alternative and Complementary Medicne, 11 (4): pp

Ettinger B and Grady D . The waning effect of postmenopausal estrogen therapy
on osteoporosis. N Eng J Med 1993; 329: 1192-1193

Grady D, Gebretsadik T, et al. Hormone replacement therapy and
endometrial cancer risk: ameta-analysis. Obstet Gynecol 1995; 85: 304-313

Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Vasomotor symptoms and well-being in the climacteric years. Maturitas 1996;23:293–9.

Hahn PM, Wong J, Reid RL. Menopausal-like hot flashes reported in women of reproductive age. Fertil Steril 1998;70:913– 8.

Herrington DM, Reboussin DM, et al. Effects of estrogen replacement on the
progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-529

Manson JE and Martin KA. Postmenopausal hormone-replacement therapy.
N Engl J Med 2001; 345: 34-40

Mulnard RA, Cotman CW, et al. Estrogen replacement therapy for treatment
of mild to moderate Alzheimers disease. JAMA 2000; 283: 1007-1015

Rodriguez C, Patel AV, et al. Estrogen replacement therapy and ovarian cancer
mortality in a large prospective study of US women. JAMA 2001; 285: 1460-1465